Karuna Therapeutics Announces Proposed Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil settles up 2% after Trump rejects return to Iran ceasefire deal terms
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Revolution Medicines prices RASONQUE at $39,800 per month
Karuna Therapeutics Inc. (KRTX) PT Raised to $165 at RBC Capital, Sees Underappreciated De-Risking
March 1, 2021 6:50 AM ESTRBC Capital analyst Brian Abrahams raised the price target on Karuna Therapeutics Inc. (NASDAQ: KRTX) to $165.00 (from $160.00) while maintaining a Outperform rating.
The analyst comments "Late last week, KRTX reported preliminary qualitative data from its ph.Ib study of lead drug KarXT in... More
